Deciphera Pharmaceuticals News Today

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report)’s stock price hit a new 52-week high during trading on Monday . The company traded as high as $25.59 and last traded at $25.58, with a volume of 366347 shares changing hands. The stock had previously closed at $25.57. Analysts Set New Price Targets A number of […]

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) have been assigned a consensus recommendation of “Hold” from the ten brokerages that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month […]

Global law firm Greenberg Traurig, LLP represented Japan-based global specialty pharmaceutical company ONO Pharmaceutical Co. in its acquisition of Waltham, Massachusetts-based Deciphera Pharmaceuticals for $25.60 per share in cash, for a total equity value of $2.4 billion.

Guggenheim reaffirmed their neutral rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. Other analysts have also recently issued research reports about the company. Jonestrading restated a hold rating and set a $25.60 target price on shares of Deciphera Pharmaceuticals in a report […]

Jefferies Financial Group restated their hold rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a report released on Monday, Benzinga reports. Jefferies Financial Group currently has a $25.60 price target on the stock, down from their prior price target of $26.00. DCPH has been the topic of several other research reports. Jonestrading […]

Jonestrading restated their hold rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. Jonestrading currently has a $25.60 price objective on the stock. Several other research firms also recently weighed in on DCPH. JPMorgan Chase & Co. lifted their target price on […]

Jonestrading restated their hold rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a report released on Monday morning, Benzinga reports. They currently have a $25.60 price objective on the stock. Several other research analysts also recently issued reports on DCPH. Stifel Nicolaus raised their price objective on shares of Deciphera Pharmaceuticals from […]

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 1,116,913 shares changed hands during mid-day trading, a decline of 1% from the previous session’s volume of 1,129,558 shares.The stock last traded at $25.30 and had previously closed at $25.28. Analyst Ratings Changes Several research firms have […]

OSAKA -- Ono Pharmaceutical plans to purchase an American cancer drug maker for $2.4 billion in its largest acquisition yet, seeking growth with new-d

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Deciphera Pharmaceuticals, Inc. to ONO...